Fig. 1
a Preparation procedure of the Fe-PHCN@DOX nano-nuclear-reactors. b Schematic illustration of synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy through (I) ICD effect; (II) nanobody blockade; (III) hypoxia modulation. The label ①,②,③,④,⑤ represents PTT effect, DOX-induced cytotoxicity and H2O2 generation, nanocatalytic effect, GSH depletion, catalase-like effect, respectively